GetTopicDetailResponse(id=7b8e145426e, topicName=power, introduction=power, content=null, image=null, comments=5, allHits=884, url=https://h5.medsci.cn/topic?id=14542, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=42154, tagList=[TagDto(tagId=42154, tagName=power)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1791451, encodeId=655e1e914515e, content=<a href='/topic/show?id=7b8e145426e' target=_blank style='color:#2F92EE;'>#power#</a>, objectTitle=IMpower010研究生存數(shù)據(jù)首次公布，夯實阿替利珠單抗為標(biāo)準(zhǔn)輔助治療方案！| WCLC 2022速遞, objectType=article, longId=735782, objectId=d1d6e3578230, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1d6e3578230, replyNumber=0, likeNumber=117, createdTime=2022-11-15, rootId=0, userName=醫(yī)者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1d6e3578230, moduleTitle=IMpower010研究生存數(shù)據(jù)首次公布，夯實阿替利珠單抗為標(biāo)準(zhǔn)輔助治療方案！| WCLC 2022速遞, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=d1d6e3578230)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1791450, encodeId=bac51e91450e8, content=<a href='/topic/show?id=7b8e145426e' target=_blank style='color:#2F92EE;'>#power#</a>, objectTitle=ESMO：阿替利珠單抗輔助治療可以減少II-IIIA期NSCLC術(shù)后復(fù)發(fā)風(fēng)險（IMpower010研究）, objectType=article, longId=301718, objectId=f3b0301e18e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3b0301e18e1, replyNumber=0, likeNumber=99, createdTime=2022-07-27, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3b0301e18e1, moduleTitle=ESMO：阿替利珠單抗輔助治療可以減少II-IIIA期NSCLC術(shù)后復(fù)發(fā)風(fēng)險（IMpower010研究）, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f3b0301e18e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1791449, encodeId=1da51e9144918, content=<a href='/topic/show?id=7b8e145426e' target=_blank style='color:#2F92EE;'>#power#</a>, objectTitle=Lancet：EGFR野生型的早期NSCLC患者，免疫治療獲益顯著（IMpower010研究）, objectType=article, longId=217564, objectId=4a9821e5642b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a9821e5642b, replyNumber=0, likeNumber=96, createdTime=2021-12-25, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a9821e5642b, moduleTitle=Lancet：EGFR野生型的早期NSCLC患者，免疫治療獲益顯著（IMpower010研究）, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=4a9821e5642b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1791447, encodeId=ae2a1e91447c3, content=<a href='/topic/show?id=7b8e145426e' target=_blank style='color:#2F92EE;'>#power#</a>, objectTitle= J Clin Oncol：卡鉑/依托泊苷方案+阿妥珠單抗作為廣泛期小細(xì)胞肺癌一線治療方案的延長隨訪預(yù)后結(jié)果（IMpower133試驗）, objectType=article, longId=205905, objectId=050d20590572, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=050d20590572, replyNumber=0, likeNumber=122, createdTime=2021-05-06, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=050d20590572, moduleTitle= J Clin Oncol：卡鉑/依托泊苷方案+阿妥珠單抗作為廣泛期小細(xì)胞肺癌一線治療方案的延長隨訪預(yù)后結(jié)果（IMpower133試驗）, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=050d20590572)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1791448, encodeId=eb4a1e9144878, content=<a href='/topic/show?id=7b8e145426e' target=_blank style='color:#2F92EE;'>#power#</a>, objectTitle=J Thorac Oncol:阿替利珠單抗（atezolizumab）聯(lián)合貝伐珠單抗+化療一線治療轉(zhuǎn)移性非鱗狀非小細(xì)胞肺癌的最終OS分析：IMpower150, objectType=article, longId=214763, objectId=e0a7214e632f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0a7214e632f, replyNumber=0, likeNumber=90, createdTime=2022-03-03, rootId=0, userName=naiwu77, userId=5b0e350, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0a7214e632f, moduleTitle=J Thorac Oncol:阿替利珠單抗（atezolizumab）聯(lián)合貝伐珠單抗+化療一線治療轉(zhuǎn)移性非鱗狀非小細(xì)胞肺癌的最終OS分析：IMpower150, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=e0a7214e632f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
